An implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (CMM)

T. J. Smith, P. J. Coyne, P. S. Staats, T. Deer, L. J. Stearns, R. L. Rauck, R. L. Boortz-Marx, E. Buchser, E. Català, D. A. Bryce, M. Cousins, G. E. Pool, M. Wallace, T. Yaksh, S. Magnuson, A. Leung, F. Ahadian, S. Bullock, M. McBeth, A. HoyeR. Miguel, M. A. Weitzner, L. Balducci, K. Follett, P. Hitchon, W. S. Minore, H. Weiss, J. Jaworowicz, S. Croy, S. Davis, S. Grossman, M. Grieb, L. Carson, S. Mitchell, M. Stuckey, S. Charapata, M. McCracken, R. Sorensen, J. Calava, J. Dunn, P. Kosek, S. Weinstein, T. K. Banerjee, D. Caraway, C. Kim, M. Serafini, K. McNeil, J. Frame, G. Orlandini, A. Siragusa, F. Aliaga, A. Lopez-Pousa, C. Pericay, L. Perey, C. Muriel, F. Boyle, A. Molloy, C. Brooker, S. E. Walker

Research output: Contribution to journal › Article › peer-review

126 Scopus citations

Fingerprint

Dive into the research topics of 'An implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (CMM)'. Together they form a unique fingerprint.

Medicine & Life Sciences